113 related articles for article (PubMed ID: 22669803)
1. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
Murphy CE
Ann Pharmacother; 2012 Jun; 46(6):812-21. PubMed ID: 22669803
[TBL] [Abstract][Full Text] [Related]
2. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
[TBL] [Abstract][Full Text] [Related]
5. Exenatide: a new option for the treatment of type 2 diabetes.
Yoo BK; Triller DM; Yoo DJ
Ann Pharmacother; 2006 Oct; 40(10):1777-84. PubMed ID: 16985091
[TBL] [Abstract][Full Text] [Related]
6. Exenatide for once-weekly administration.
Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
[TBL] [Abstract][Full Text] [Related]
8. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
[TBL] [Abstract][Full Text] [Related]
9. Exenatide once weekly in type 2 diabetes mellitus.
Bischoff LA; Jabbour SA; Miller JL
Expert Opin Pharmacother; 2011 Jun; 12(8):1297-1303. PubMed ID: 21548720
[No Abstract] [Full Text] [Related]
10. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS; Mace KF; Diamant M; Darsow T; Cirincione BB; Booker Porter TK; Kinninger LA; Trautmann ME
Diabetes Obes Metab; 2012 Jun; 14(6):546-54. PubMed ID: 22236356
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
Doggrell SA
Expert Opin Pharmacother; 2011 Sep; 12(13):2055-67. PubMed ID: 21534885
[TBL] [Abstract][Full Text] [Related]
12. Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
Scott LJ
Drugs; 2012 Aug; 72(12):1679-707. PubMed ID: 22867046
[TBL] [Abstract][Full Text] [Related]
13. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
14. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
[TBL] [Abstract][Full Text] [Related]
15. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.
Iwamoto K; Nasu R; Yamamura A; Kothare PA; Mace K; Wolka AM; Linnebjerg H
Endocr J; 2009; 56(8):951-62. PubMed ID: 19706990
[TBL] [Abstract][Full Text] [Related]
17. Exenatide. Amylin/Eli Lilly.
Giannoukakis N
Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
[TBL] [Abstract][Full Text] [Related]
18. Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
Syed YY; McCormack PL
Drugs; 2015 Jul; 75(10):1141-52. PubMed ID: 26071140
[TBL] [Abstract][Full Text] [Related]
19. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
